HRP20180953T1 - Supstituirani 3-haloalilaminski inhibitori za ssao i njihove uporabe - Google Patents

Supstituirani 3-haloalilaminski inhibitori za ssao i njihove uporabe

Info

Publication number: HRP20180953T1
Authority: HR; Croatia
Prior art keywords: ssao; substituted; haloallylamine; inhibitors; haloallylamine inhibitors
Prior art date: 2012-05-02

Application number

HRP20180953TT

Other languages

English (en)

Inventor

Mandar Deodhar

Alison Dorothy Findlay

Jonathan Stuart Foot

Wolfgang JAROLIMEK

Ian Alexander Mcdonald

Alan Robertson

Craig Ivan Turner

Original Assignee

Boehringer Ingelheim International Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-05-02

Filing date

2018-06-19

Publication date

2018-07-27

2018-06-19 Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh

2018-07-27 Publication of HRP20180953T1 publication Critical patent/HRP20180953T1/hr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/46—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C321/00—Thiols, sulfides, hydropolysulfides or polysulfides
- C07C321/24—Thiols, sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
- C07C321/26—Thiols
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
- C07C323/63—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)
Endocrinology (AREA)
Orthopedic Medicine & Surgery (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Obesity (AREA)
Immunology (AREA)
Vascular Medicine (AREA)
Physical Education & Sports Medicine (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Gastroenterology & Hepatology (AREA)
Dermatology (AREA)
Emergency Medicine (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

HRP20180953TT 2012-05-02 2018-06-19 Supstituirani 3-haloalilaminski inhibitori za ssao i njihove uporabe HRP20180953T1 (hr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201261641814P	2012-05-02	2012-05-02
PCT/AU2013/000356 WO2013163675A1 (en)	2012-05-02	2013-04-05	Substituted 3-haloallylamine inhibitors of ssao and uses thereof
EP13784562.4A EP2844637B1 (en)	2012-05-02	2013-04-05	Substituted 3-haloallylamine inhibitors of ssao and uses thereof

Publications (1)

Publication Number	Publication Date
HRP20180953T1 true HRP20180953T1 (hr)	2018-07-27

Family

ID=49514094

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HRP20180953TT HRP20180953T1 (hr)	2012-05-02	2018-06-19	Supstituirani 3-haloalilaminski inhibitori za ssao i njihove uporabe

Country Status (25)

Country	Link
US (4)	US9302986B2 (hr)
EP (2)	EP2844637B1 (hr)
JP (3)	JP6182595B2 (hr)
KR (2)	KR102089935B1 (hr)
CN (2)	CN104520268B (hr)
AU (2)	AU2013255103B2 (hr)
BR (1)	BR112014027406B1 (hr)
CA (2)	CA2871793C (hr)
CY (1)	CY1120334T1 (hr)
DK (1)	DK2844637T5 (hr)
ES (1)	ES2668300T3 (hr)
HK (2)	HK1203477A1 (hr)
HR (1)	HRP20180953T1 (hr)
HU (1)	HUE038437T2 (hr)
LT (1)	LT2844637T (hr)
ME (1)	ME03063B (hr)
MX (2)	MX377635B (hr)
NO (1)	NO2842608T3 (hr)
PL (1)	PL2844637T3 (hr)
PT (1)	PT2844637T (hr)
RS (1)	RS57086B1 (hr)
SG (2)	SG10201707020TA (hr)
SI (1)	SI2844637T1 (hr)
TR (1)	TR201807453T4 (hr)
WO (1)	WO2013163675A1 (hr)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT2844637T (pt) *	2012-05-02	2018-04-17	Boehringer Ingelheim Int	Inibidores de 3-haloalilamina substituídos de ssao e as suas utilizações
GB201304526D0 (en)	2013-03-13	2013-04-24	Proximagen Ltd	New compounds
WO2015189534A1 (en)	2014-06-12	2015-12-17	Proximagen Limited	Vap-1 inhibitors for treating muscular dystrophy
JP2018076236A (ja) *	2015-06-05	2018-05-17	株式会社アールテック・ウエノ	がんを処置するための医薬組成物
AU2016366635A1 (en)	2015-12-07	2018-06-21	Benevolentai Cambridge Limited	VAP-1 inhibitors for treating pain
EP3414226A4 (en)	2016-02-12	2019-12-18	Pharmaxis Ltd.	INDOL AND AZAINDOL HALOALLYLAMINE DERIVATIVE INHIBITORS OF LYSYLOXIDASES AND USES THEREOF
WO2018027892A1 (en) *	2016-08-12	2018-02-15	Eli Lilly And Company	Amino pyrimidine ssao inhibitors
MX2019004549A (es) *	2016-10-19	2019-06-12	Boehringer Ingelheim Int	Combinaciones que comprenden un inhibidor ssao/vap-1 y un inhibidor sglt2 y usos de los mismos.
EP3558363A1 (en)	2016-12-21	2019-10-30	Amgen Inc.	Anti-tnf alpha antibody formulations
CN108341752B (zh) *	2017-01-21	2022-12-23	广东东阳光药业有限公司	抑制ssao/vap-1的胺类化合物及其在医药上的应用
WO2018148856A1 (en) *	2017-02-14	2018-08-23	Eli Lilly And Company	Diazaspirodecanyl-pyrimidine compounds useful as ssao inhibitors
PL3589606T3 (pl)	2017-03-01	2024-03-04	Boehringer Ingelheim International Gmbh	Dekarboksylowanie pochodnych kwasu alfa-halogenoakrylowego katalizowane metalem przejściowym
AU2018226610A1 (en) *	2017-03-02	2019-09-05	Pharmaxis Ltd.	Haloallylamine pyrazole derivative inhibitors of lysyl oxidases and uses thereof
EP3617186A1 (en) *	2017-04-28	2020-03-04	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	Fluoroallylamine derivative and use thereof
KR20200013714A (ko)	2017-05-31	2020-02-07	베링거 인겔하임 인터내셔날 게엠베하	(e)-4-(2-(아미노메틸)-3-플루오로알릴옥시)-n-3급-부틸벤즈아미드를 포함하는 약제학적 조성물 및 약제학적 투여 형태, 이들의 제조 방법, 이의 치료 방법 및 용도
GB201709136D0 (en) *	2017-06-08	2017-07-26	Proximagen Ltd	New therapeutic uses of enzyme inhibitors
CN110719902B (zh) *	2017-06-20	2022-08-12	山东丹红制药有限公司	Ssao抑制剂
CN109251166B (zh) *	2017-07-13	2021-11-05	广东东阳光药业有限公司	抑制ssao/vap-1的胺类化合物及其在医药上的应用
WO2019024924A1 (zh) *	2017-08-04	2019-02-07	广东东阳光药业有限公司	抑制ssao/vap-1的胺类化合物及其在医药上的应用
CN109810041B (zh)	2017-11-21	2023-08-15	药捷安康(南京)科技股份有限公司	卤代烯丙基胺类ssao/vap-1抑制剂及其应用
CN109988109B (zh)	2017-12-29	2020-12-29	广东东阳光药业有限公司	抑制ssao/vap-1的胺类化合物及其用途
CN109988106B (zh) *	2017-12-29	2023-03-31	广东东阳光药业有限公司	抑制ssao/vap-1的胺类化合物及其在医药上的应用
KR20190110736A (ko)	2018-03-21	2019-10-01	주식회사유한양행	신규의 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
KR20190110740A (ko)	2018-03-21	2019-10-01	주식회사유한양행	신규의 아릴 또는 헤테로아릴 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
AU2019238090B2 (en)	2018-03-22	2024-08-01	Viking Therapeutics, Inc.	Crystalline forms and methods of producing crystalline forms of a compound
WO2020006177A1 (en) *	2018-06-29	2020-01-02	Blade Therapeutics, Inc.	Vascular adhesion protein-1 (vap-1) modulators and therapeutic uses thereof
KR20200004036A (ko) *	2018-07-03	2020-01-13	주식회사유한양행	(e)-(2-(클로로메틸)-3-플루오로알릴)카바메이트 유도체의 제조방법
CA3105599A1 (en) *	2018-08-03	2020-02-06	Pharmaxis Ltd.	Haloallylamine sulfone derivative inhibitors of lysyl oxidases and uses thereof
CN110938059A (zh) *	2018-09-25	2020-03-31	上海轶诺药业有限公司	胺基脲敏感性胺氧化酶抑制剂制备及其应用
WO2020063854A1 (zh) *	2018-09-27	2020-04-02	南京明德新药研发有限公司	作为vap-1抑制剂的喹啉类衍生物
BR112021005920A2 (pt) *	2018-09-28	2021-06-29	Acucela Inc.	inibidores de vap-1
CA3114208A1 (en) *	2018-09-28	2020-04-02	Acucela Inc.	Inhibitors of vap-1
US20220002309A1 (en) *	2018-10-24	2022-01-06	Metacrine, Inc.	Ssao inhibitors and uses thereof
CA3112510A1 (en)	2018-10-29	2020-05-07	Boehringer Ingelheim International Gmbh	Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
JP7425793B2 (ja) *	2018-10-29	2024-01-31	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	ピリジニルスルホンアミド誘導体、医薬組成物およびそれらの使用
US12102646B2 (en)	2018-12-05	2024-10-01	Viking Therapeutics, Inc.	Compositions for the treatment of fibrosis and inflammation
EP3890748A4 (en) *	2018-12-05	2022-12-21	Viking Therapeutics, Inc.	COMPOSITIONS AND METHODS FOR TREATING HEPATIC DISORDERS
TWI835945B (zh) *	2018-12-14	2024-03-21	南韓商柳韓洋行股份有限公司	3,3-二氟烯丙胺化物或其鹽及包含彼的醫藥組合物
TW202039486A (zh)	2018-12-14	2020-11-01	南韓商柳韓洋行股份有限公司	三唑并吡啶-3-酮化物或其鹽及包含彼之醫藥組合物
WO2020125776A1 (zh)	2018-12-20	2020-06-25	山东丹红制药有限公司	式(iv)化合物的工艺路线、晶型及其制备方法
BR112021013429A2 (pt) *	2019-01-11	2021-10-19	Nanjing Transthera Biosciences Co., Ltd.	Composto, composição farmacêutica, e, uso do composto
CN113748104B (zh) *	2019-05-20	2024-02-27	广东东阳光药业股份有限公司	抑制ssao/vap-1的异喹啉酮类化合物及其用途
CA3145738A1 (en) *	2019-07-25	2021-01-28	Pharmaxis Ltd.	Difluorohaloallylamine sulfone derivative inhibitors of lysyl oxidases, methods of preparation, and uses thereof
CN114901649B (zh) *	2019-10-29	2024-07-23	诚益生物(美国)公司	Ssao抑制剂及其用途
CN114728925B (zh) *	2019-11-28	2023-12-08	广东东阳光药业股份有限公司	一种作为ssao/vap-1抑制剂的胺类衍生物及其用途
US20230127498A1 (en) *	2020-03-25	2023-04-27	Terns, Inc.	Treatment of respiratory disorders
CN111654920B (zh) *	2020-06-02	2022-03-11	重庆邮电大学	一种分布式能效子载波功率分配方法
CN115916337A (zh) *	2020-06-26	2023-04-04	法玛西斯有限公司	卤代烯丙基胺双胺氧化酶抑制剂
AU2021332217A1 (en)	2020-08-25	2023-05-11	Eli Lilly And Company	Polymorphs of an ssao inhibitor
CN114621243B (zh) *	2020-12-14	2024-03-01	上海拓界生物医药科技有限公司	一种磺酰胺类衍生物及其用途
CN114621189B (zh) *	2020-12-14	2024-01-02	上海拓界生物医药科技有限公司	一种内酰胺类衍生物及其用途
CN114621190B (zh) *	2020-12-14	2023-12-05	上海拓界生物医药科技有限公司	一种烯丙基胺类衍生物及其用途
WO2024044813A1 (en) *	2022-08-29	2024-03-07	Pharmaxis Ltd.	Novel selective inhibitors of lysyl oxidases
US20240390332A1 (en)	2023-05-24	2024-11-28	Boehringer Ingelheim Vetmedica Gmbh	Combination treatment and/or prevention of renal diseases and/or hypertension in non-human mammals comprising one or more SGLT-2 inhibitors and telmisartan

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3710795A (en)	1970-09-29	1973-01-16	Alza Corp	Drug-delivery device with stretched, rate-controlling membrane
GB1429184A (en)	1972-04-20	1976-03-24	Allen & Hanburys Ltd	Physically anti-inflammatory steroids for use in aerosols
US4044126A (en)	1972-04-20	1977-08-23	Allen & Hanburys Limited	Steroidal aerosol compositions and process for the preparation thereof
USRE28819E (en)	1972-12-08	1976-05-18	Syntex (U.S.A.) Inc.	Dialkylated glycol compositions and medicament preparations containing same
US4410545A (en)	1981-02-13	1983-10-18	Syntex (U.S.A.) Inc.	Carbonate diester solutions of PGE-type compounds
US4328245A (en)	1981-02-13	1982-05-04	Syntex (U.S.A.) Inc.	Carbonate diester solutions of PGE-type compounds
US4358603A (en)	1981-04-16	1982-11-09	Syntex (U.S.A.) Inc.	Acetal stabilized prostaglandin compositions
US4454158A (en)	1981-06-01	1984-06-12	Merrell Toraude Et Compagnie	Allyl amine MAO inhibitors
US4409239A (en)	1982-01-21	1983-10-11	Syntex (U.S.A.) Inc.	Propylene glycol diester solutions of PGE-type compounds
US4522811A (en)	1982-07-08	1985-06-11	Syntex (U.S.A.) Inc.	Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
ZA855101B (en) *	1984-07-13	1986-05-28	Merrell Dow Pharma	Fluoroallylaine derivatives
US4699928A (en)	1984-07-13	1987-10-13	Merrell Dow Pharmaceuticals Inc.	Fluoroallylamine derivatives
US4650907A (en)	1985-12-05	1987-03-17	Merrell Dow Pharmaceuticals Inc.	Nonaromatic fluoroallylamine MAO inhibitors
US5585112A (en)	1989-12-22	1996-12-17	Imarx Pharmaceutical Corp.	Method of preparing gas and gaseous precursor-filled microspheres
IT1246382B (it)	1990-04-17	1994-11-18	Eurand Int	Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5543390A (en)	1990-11-01	1996-08-06	State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University	Covalent microparticle-drug conjugates for biological targeting
US6010715A (en)	1992-04-01	2000-01-04	Bertek, Inc.	Transdermal patch incorporating a polymer film incorporated with an active agent
US6024975A (en)	1992-04-08	2000-02-15	Americare International Diagnostics, Inc.	Method of transdermally administering high molecular weight drugs with a polymer skin enhancer
US6274552B1 (en)	1993-03-18	2001-08-14	Cytimmune Sciences, Inc.	Composition and method for delivery of biologically-active factors
US5523092A (en)	1993-04-14	1996-06-04	Emory University	Device for local drug delivery and methods for using the same
US5985307A (en)	1993-04-14	1999-11-16	Emory University	Device and method for non-occlusive localized drug delivery
US6004534A (en)	1993-07-23	1999-12-21	Massachusetts Institute Of Technology	Targeted polymerized liposomes for improved drug delivery
US5759542A (en)	1994-08-05	1998-06-02	New England Deaconess Hospital Corporation	Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5660854A (en)	1994-11-28	1997-08-26	Haynes; Duncan H	Drug releasing surgical implant or dressing material
US5983134A (en)	1995-04-23	1999-11-09	Electromagnetic Bracing Systems Inc.	Electrophoretic cuff apparatus drug delivery system
US6316652B1 (en)	1995-06-06	2001-11-13	Kosta Steliou	Drug mitochondrial targeting agents
US6167301A (en)	1995-08-29	2000-12-26	Flower; Ronald J.	Iontophoretic drug delivery device having high-efficiency DC-to-DC energy conversion circuit
US6039975A (en)	1995-10-17	2000-03-21	Hoffman-La Roche Inc.	Colon targeted delivery system
TW345603B (en)	1996-05-29	1998-11-21	Gmundner Fertigteile Gmbh	A noise control device for tracks
US5985317A (en)	1996-09-06	1999-11-16	Theratech, Inc.	Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
EP1007012A4 (en)	1996-10-01	2006-01-18	Cima Labs Inc	TASTE MASKING MICROCAPSULE COMPOSITIONS AND METHODS OF MAKING
US6131570A (en)	1998-06-30	2000-10-17	Aradigm Corporation	Temperature controlling device for aerosol drug delivery
US5860957A (en)	1997-02-07	1999-01-19	Sarcos, Inc.	Multipathway electronically-controlled drug delivery system
US6120751A (en)	1997-03-21	2000-09-19	Imarx Pharmaceutical Corp.	Charged lipids and uses for the same
US6060082A (en)	1997-04-18	2000-05-09	Massachusetts Institute Of Technology	Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US5948433A (en)	1997-08-21	1999-09-07	Bertek, Inc.	Transdermal patch
AU730850B2 (en)	1997-10-28	2001-03-15	Bando Chemical Industries, Ltd.	A transdermal patch and a method for manufacture of a substrate sheet therefor
US6048736A (en)	1998-04-29	2000-04-11	Kosak; Kenneth M.	Cyclodextrin polymers for carrying and releasing drugs
US6271359B1 (en)	1999-04-14	2001-08-07	Musc Foundation For Research Development	Tissue-specific and pathogen-specific toxic agents and ribozymes
US6256533B1 (en)	1999-06-09	2001-07-03	The Procter & Gamble Company	Apparatus and method for using an intracutaneous microneedle array
US6261595B1 (en)	2000-02-29	2001-07-17	Zars, Inc.	Transdermal drug patch with attached pocket for controlled heating device
WO2004018997A2 (en)	2002-08-20	2004-03-04	Neurogenetics, Inc.	Methods and compositions for modulating amyloid beta
EP2283833A3 (en)	2004-02-25	2013-07-10	La Jolla Pharmaceutical Co.	Amines and amides for the treatment of diseases
CN1921841A (zh) *	2004-02-25	2007-02-28	拉卓拉药物公司	用于治疗疾病的胺和酰胺类化合物
WO2007005737A2 (en)	2005-07-01	2007-01-11	Case Western Reserve University	Amine oxidase inhibitors
EP2004166A2 (en) *	2006-03-31	2008-12-24	La Jolla Pharmaceutical Company	Inhibitors of semicarbazide-sensitive amine oxidase (ssao) and vap-1 mediated adhesion useful for treatment and prevention of diseases
AU2007275737A1 (en)	2006-07-19	2008-01-24	Osurf	Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof
CA2702885A1 (en)	2007-10-19	2009-04-23	R-Tech Ueno, Ltd.	Pharmaceutical composition for treatment of cataract
WO2009061830A1 (en)	2007-11-06	2009-05-14	Massachusetts Eye & Ear Infirmary	Methods and compositions for treating conditions associated with angiogenesis using a vascular adhesion protein-1 (vap-1) inhibitor
JP2011504485A (ja) *	2007-11-21	2011-02-10	ファーマクシスリミテッド	Ｓｓａｏ／ｖａｐ−１のハロアリルアミン阻害剤およびその用途
UA112154C2 (uk)	2009-09-08	2016-08-10	Біоті Терапіс Корп.	Застосування повністю людського анти-vap-1-антитіла для лікування фіброзних станів
GB201004311D0 (en) *	2010-03-15	2010-04-28	Proximagen Ltd	New enzyme inhibitor compounds
PT2844637T (pt) *	2012-05-02	2018-04-17	Boehringer Ingelheim Int	Inibidores de 3-haloalilamina substituídos de ssao e as suas utilizações

2013
- 2013-04-05 PT PT137845624T patent/PT2844637T/pt unknown
- 2013-04-05 SG SG10201707020TA patent/SG10201707020TA/en unknown
- 2013-04-05 CN CN201380035139.3A patent/CN104520268B/zh active Active
- 2013-04-05 TR TR2018/07453T patent/TR201807453T4/tr unknown
- 2013-04-05 EP EP13784562.4A patent/EP2844637B1/en active Active
- 2013-04-05 RS RS20180464A patent/RS57086B1/sr unknown
- 2013-04-05 BR BR112014027406-1A patent/BR112014027406B1/pt active IP Right Grant
- 2013-04-05 LT LTEP13784562.4T patent/LT2844637T/lt unknown
- 2013-04-05 ME MEP-2018-104A patent/ME03063B/me unknown
- 2013-04-05 PL PL13784562T patent/PL2844637T3/pl unknown
- 2013-04-05 US US14/397,931 patent/US9302986B2/en active Active
- 2013-04-05 CN CN201710329198.1A patent/CN107266332B/zh not_active Expired - Fee Related
- 2013-04-05 DK DK13784562.4T patent/DK2844637T5/en active
- 2013-04-05 MX MX2018009129A patent/MX377635B/es unknown
- 2013-04-05 SI SI201331052T patent/SI2844637T1/en unknown
- 2013-04-05 ES ES13784562.4T patent/ES2668300T3/es active Active
- 2013-04-05 KR KR1020147032073A patent/KR102089935B1/ko active Active
- 2013-04-05 MX MX2014013294A patent/MX360634B/es active IP Right Grant
- 2013-04-05 JP JP2015509257A patent/JP6182595B2/ja active Active
- 2013-04-05 WO PCT/AU2013/000356 patent/WO2013163675A1/en active Application Filing
- 2013-04-05 CA CA2871793A patent/CA2871793C/en active Active
- 2013-04-05 EP EP18151119.7A patent/EP3438087A1/en not_active Withdrawn
- 2013-04-05 KR KR1020207007076A patent/KR20200030126A/ko not_active Ceased
- 2013-04-05 AU AU2013255103A patent/AU2013255103B2/en active Active
- 2013-04-05 HU HUE13784562A patent/HUE038437T2/hu unknown
- 2013-04-05 CA CA3086105A patent/CA3086105A1/en not_active Abandoned
- 2013-04-05 SG SG11201406948PA patent/SG11201406948PA/en unknown
- 2013-04-11 AU AU2013203655A patent/AU2013203655B2/en not_active Ceased
2014
- 2014-08-27 NO NO14182515A patent/NO2842608T3/no unknown
2015
- 2015-04-20 HK HK15103821.2A patent/HK1203477A1/xx not_active IP Right Cessation
2016
- 2016-02-26 US US15/054,243 patent/US9815782B2/en active Active
2017
- 2017-02-06 JP JP2017019542A patent/JP6602802B2/ja not_active Expired - Fee Related
- 2017-10-05 US US15/725,363 patent/US10160723B2/en not_active Expired - Fee Related
2018
- 2018-04-04 HK HK18104502.3A patent/HK1245237A1/zh unknown
- 2018-06-14 CY CY20181100626T patent/CY1120334T1/el unknown
- 2018-06-19 HR HRP20180953TT patent/HRP20180953T1/hr unknown
- 2018-11-01 US US16/177,841 patent/US20190071396A1/en not_active Abandoned
2019
- 2019-10-09 JP JP2019185763A patent/JP2020019810A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
US20180086698A1 (en)	2018-03-29
KR102089935B1 (ko)	2020-03-18
CA3086105A1 (en)	2013-11-07
JP2015521167A (ja)	2015-07-27
CA2871793C (en)	2020-09-15
AU2013203655A1 (en)	2013-11-21
DK2844637T5 (en)	2018-08-13
JP6182595B2 (ja)	2017-08-16
SG10201707020TA (en)	2017-10-30
JP6602802B2 (ja)	2019-11-06
US10160723B2 (en)	2018-12-25
AU2013255103A1 (en)	2014-11-06
PL2844637T3 (pl)	2018-09-28
MX360634B (es)	2018-11-12
NO2842608T3 (hr)	2018-07-21
ES2668300T3 (es)	2018-05-17
US9302986B2 (en)	2016-04-05
BR112014027406A2 (pt)	2017-06-27
MX2014013294A (es)	2015-05-08
EP3438087A1 (en)	2019-02-06
KR20200030126A (ko)	2020-03-19
US20190071396A1 (en)	2019-03-07
US9815782B2 (en)	2017-11-14
CY1120334T1 (el)	2019-07-10
CN104520268B (zh)	2017-05-24
AU2013203655B2 (en)	2017-02-02
HUE038437T2 (hu)	2018-10-29
WO2013163675A1 (en)	2013-11-07
CN104520268A (zh)	2015-04-15
DK2844637T3 (en)	2018-04-23
CN107266332B (zh)	2020-07-24
US20160244406A1 (en)	2016-08-25
EP2844637A1 (en)	2015-03-11
KR20150014926A (ko)	2015-02-09
EP2844637B1 (en)	2018-03-28
JP2020019810A (ja)	2020-02-06
US20150158813A1 (en)	2015-06-11
HK1203477A1 (en)	2015-10-30
HK1245237A1 (zh)	2018-08-24
TR201807453T4 (tr)	2018-06-21
JP2017132767A (ja)	2017-08-03
EP2844637A4 (en)	2015-12-09
SG11201406948PA (en)	2014-11-27
CN107266332A (zh)	2017-10-20
BR112014027406B1 (pt)	2020-09-24
ME03063B (me)	2019-01-20
AU2013255103B2 (en)	2016-09-29
LT2844637T (lt)	2018-05-10
CA2871793A1 (en)	2013-11-07
PT2844637T (pt)	2018-04-17
MX377635B (es)	2025-03-11
RS57086B1 (sr)	2018-06-29
SI2844637T1 (en)	2018-07-31

Publication	Publication Date	Title
HRP20180953T1 (hr)	2018-07-27	Supstituirani 3-haloalilaminski inhibitori za ssao i njihove uporabe
HRP20181628T1 (hr)	2018-12-14	Spojevi i postupci za njihovu upotrebu
IL237849B (en)	2020-01-30	ret suppressors and their uses
HK1208439A1 (en)	2016-03-04	5-azaindazole compounds and methods of use 5-
EP2678018A4 (en)	2015-09-30	COMBINATION OF CHINESE HEMMER AND USES THEREOF
HK1202333A1 (en)	2015-09-25	Combination of kinase inhibitors and uses thereof
SG11201504022RA (en)	2015-06-29	Glutamase inhibitors and method of use
EP2834421A4 (en)	2016-07-06	STABILIZING AGENTS AND METHODS OF USE
HK1198827A1 (en)	2015-06-12	Dyrk1 inhibitors and uses thereof dyrk1
HK1202112A1 (en)	2015-09-18	Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase
EP2928384A4 (en)	2016-08-03	ANCHORS CAPTURED BY THE FABRIC AND METHOD OF USE
HK1206264A1 (en)	2016-01-08	Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof -3-
HK1207968A1 (en)	2016-02-19	Usp30 inhibitors and methods of use usp30
EP2852397A4 (en)	2016-03-23	HUWENTOXIN IV VARIANTS AND METHODS OF USE
HK1206282A1 (en)	2016-01-08	Tfpi inhibitors and methods of use tfpi
EP2906041A4 (en)	2016-10-26	COMPOSITIONS AND METHODS OF USING INAPPETENCE COMPOUND
HK1201066A1 (en)	2015-08-21	Pyranopyridone inhibitors of tankyrase
IL233961B (en)	2019-10-31	The composition of a phytogenic supplement and methods of its use
ZA201408128B (en)	2015-12-23	Etract of greyia radlkoferi and use thereof
HK1205695A1 (en)	2015-12-24	Paramyxovirus and methods of use